Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are effective therapies with demonstrated antineoplastic activity. Nilotinib is a second-generation FDA-approved TKI designed to overcome Imatinib resistance and intolerance in patients with chronic myelogenous leukemia (CML). Interestingly, TKIs have al...

Descripción completa

Detalles Bibliográficos
Autores principales: Contreras, Osvaldo, Villarreal, Maximiliano, Brandan, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819301/
https://www.ncbi.nlm.nih.gov/pubmed/29463296
http://dx.doi.org/10.1186/s13395-018-0150-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819301/
https://www.ncbi.nlm.nih.gov/pubmed/29463296
http://dx.doi.org/10.1186/s13395-018-0150-5

Ejemplares similares